KR20250020409A - 척수소뇌성 운동실조증을 치료하는 방법 - Google Patents
척수소뇌성 운동실조증을 치료하는 방법 Download PDFInfo
- Publication number
- KR20250020409A KR20250020409A KR1020247038718A KR20247038718A KR20250020409A KR 20250020409 A KR20250020409 A KR 20250020409A KR 1020247038718 A KR1020247038718 A KR 1020247038718A KR 20247038718 A KR20247038718 A KR 20247038718A KR 20250020409 A KR20250020409 A KR 20250020409A
- Authority
- KR
- South Korea
- Prior art keywords
- dosage form
- patient
- weeks
- hydrochloride monohydrate
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263344917P | 2022-05-23 | 2022-05-23 | |
| US63/344,917 | 2022-05-23 | ||
| PCT/US2023/067326 WO2023230451A2 (en) | 2022-05-23 | 2023-05-23 | Methods of treating spinocerebellar ataxias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250020409A true KR20250020409A (ko) | 2025-02-11 |
Family
ID=88920175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247038718A Pending KR20250020409A (ko) | 2022-05-23 | 2023-05-23 | 척수소뇌성 운동실조증을 치료하는 방법 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20260124183A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4529485A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025517509A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250020409A (cg-RX-API-DMAC7.html) |
| CN (1) | CN120018855A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023230451A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP2400349A1 (hu) * | 2024-07-05 | 2026-01-28 | Egis Gyógyszergyár Zrt. | Troriluzole-hidroklorid-sók |
| WO2026062600A1 (en) * | 2024-09-22 | 2026-03-26 | Biohaven Therapeutics Ltd. | Troriluzole for use in treating spinocerebellar ataxias |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018154462A2 (en) * | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
| PT3706739T (pt) * | 2017-11-12 | 2024-12-04 | Biohaven Therapeutics Ltd | Utilização de profármacos de riluzol para tratar ataxias |
| US20210308111A1 (en) * | 2018-07-27 | 2021-10-07 | With Great Power, Llc | Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers |
| US20230067811A1 (en) * | 2020-01-24 | 2023-03-02 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
-
2023
- 2023-05-23 JP JP2024569498A patent/JP2025517509A/ja active Pending
- 2023-05-23 US US18/867,416 patent/US20260124183A1/en active Pending
- 2023-05-23 CN CN202380041989.8A patent/CN120018855A/zh active Pending
- 2023-05-23 KR KR1020247038718A patent/KR20250020409A/ko active Pending
- 2023-05-23 WO PCT/US2023/067326 patent/WO2023230451A2/en not_active Ceased
- 2023-05-23 EP EP23812702.1A patent/EP4529485A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4529485A2 (en) | 2025-04-02 |
| WO2023230451A3 (en) | 2024-01-04 |
| JP2025517509A (ja) | 2025-06-05 |
| WO2023230451A2 (en) | 2023-11-30 |
| EP4529485A4 (en) | 2026-05-20 |
| CN120018855A (zh) | 2025-05-16 |
| US20260124183A1 (en) | 2026-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12102618B2 (en) | Use of riluzole prodrugs to treat ataxias | |
| US10285981B2 (en) | Compositions and methods for treating amyotrophic lateral sclerosis in responders | |
| TW201034665A (en) | Compositions and methods for using aminopyridines | |
| US20260124183A1 (en) | Methods of treating spinocerebellar ataxias | |
| WO2014134569A1 (en) | Compositions and methods for treating amyotrophic lateral sclerosis in responders | |
| KR20120050512A (ko) | 탈수초를 갖는 환자에서 4-아미노피리딘을 사용한 지속적 치료 | |
| WO2026011229A1 (en) | Novel therapy | |
| CN110831590A (zh) | 含有培马贝特的医药 | |
| CA2753754C (en) | Methods for treating schizophrenia | |
| US20250375459A1 (en) | Methods for ameliorating cognitive impairment using bile acid derivatives | |
| US20250275953A1 (en) | Vodobatinib for reducing progression of parkinson's disease | |
| EA049071B1 (ru) | Применение пролекарств рилузола для лечения атаксии | |
| HK40033906B (en) | Use of riluzole prodrugs to treat ataxias | |
| HK40033906A (en) | Use of riluzole prodrugs to treat ataxias | |
| HK40037184A (en) | Use of riluzole prodrugs to treat ataxias | |
| HK1160586A (en) | Durable treatment with 4-aminopyridine in patients with demyelination | |
| EP2961404A1 (en) | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |